[go: up one dir, main page]

WO2015112168A3 - Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique - Google Patents

Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique Download PDF

Info

Publication number
WO2015112168A3
WO2015112168A3 PCT/US2014/013063 US2014013063W WO2015112168A3 WO 2015112168 A3 WO2015112168 A3 WO 2015112168A3 US 2014013063 W US2014013063 W US 2014013063W WO 2015112168 A3 WO2015112168 A3 WO 2015112168A3
Authority
WO
WIPO (PCT)
Prior art keywords
noribogaine
excipient
compositions
brain barrier
blood brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/013063
Other languages
English (en)
Other versions
WO2015112168A2 (fr
Inventor
Deborah C. Mash
JR. Richard D. GLESS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DemeRx Inc
Original Assignee
DemeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DemeRx Inc filed Critical DemeRx Inc
Priority to EP14880182.2A priority Critical patent/EP3096794A2/fr
Priority to AU2014379612A priority patent/AU2014379612A1/en
Priority to PCT/US2014/013063 priority patent/WO2015112168A2/fr
Publication of WO2015112168A2 publication Critical patent/WO2015112168A2/fr
Publication of WO2015112168A3 publication Critical patent/WO2015112168A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte d'une manière générale sur des compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique.
PCT/US2014/013063 2014-01-24 2014-01-24 Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique Ceased WO2015112168A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP14880182.2A EP3096794A2 (fr) 2014-01-24 2014-01-24 Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique
AU2014379612A AU2014379612A1 (en) 2014-01-24 2014-01-24 Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
PCT/US2014/013063 WO2015112168A2 (fr) 2014-01-24 2014-01-24 Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/013063 WO2015112168A2 (fr) 2014-01-24 2014-01-24 Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique

Publications (2)

Publication Number Publication Date
WO2015112168A2 WO2015112168A2 (fr) 2015-07-30
WO2015112168A3 true WO2015112168A3 (fr) 2015-11-26

Family

ID=53682084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/013063 Ceased WO2015112168A2 (fr) 2014-01-24 2014-01-24 Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique

Country Status (3)

Country Link
EP (1) EP3096794A2 (fr)
AU (1) AU2014379612A1 (fr)
WO (1) WO2015112168A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5925634A (en) * 1989-10-20 1999-07-20 Washington University Use of ibogaine for treating neuropathic pain
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
US8637648B1 (en) * 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925634A (en) * 1989-10-20 1999-07-20 Washington University Use of ibogaine for treating neuropathic pain
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US8637648B1 (en) * 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETERSON, A. L. ET AL.: "Treatment of Parkinson's disease with trophic factors.", NEUROTHERAPEUTICS, vol. 5, no. 2, 2008, pages 270 - 280, XP022577726 *
PLOS ONE, vol. 7, no. Issue 12, 2012 *

Also Published As

Publication number Publication date
AU2014379612A1 (en) 2016-08-11
EP3096794A2 (fr) 2016-11-30
WO2015112168A2 (fr) 2015-07-30

Similar Documents

Publication Publication Date Title
WO2015168019A3 (fr) Conjugués médicament-anticorps anti-ptk7
WO2016081670A3 (fr) Agonistes partiels du récepteur de l'insuline
PT3426226T (pt) Composição oftalmológica
EP3474653A4 (fr) Moissonneuse
EP3505202A4 (fr) Ensemble équipement médical
EP3234549A4 (fr) Puce de diagnostic
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
EP3299034A4 (fr) Boîtier de stérilisation
GB201600990D0 (en) Pharmaceutical or nutritional combination
IL252683B (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
EP3281641A4 (fr) Médicament
EP3230748A4 (fr) Puce de diagnostic
EP3230721A4 (fr) Puce de diagnostic
WO2015112168A3 (fr) Compositions comprenant de la noribogaïne et un excipient pour faciliter le transport à travers la barrière hémato-encéphalique
EP3525601A4 (fr) Noyaux reconstitués à base de céréales-légumineuses
GB201500914D0 (en) Power-bet blackjack 2015
HK1219861B (en) Ophthalmoscopes
PT3445377T (pt) Composições para a pele
GB201621956D0 (en) The artifact
HK40012993A (en) Biomedical device including encapsulation
GB201618461D0 (en) Mrbr.3
AU2017133V (en) Sunbel 789 Calibrachoa hybrid
AU2017131V (en) Sunbel 871 Calibrachoa hybrid
AU2016905067A0 (en) Chamfered cannula
AU2015901453A0 (en) Improved Objects 3. 4. 15...

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014379612

Country of ref document: AU

Date of ref document: 20140124

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014880182

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014880182

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14880182

Country of ref document: EP

Kind code of ref document: A2